PD-1/PD-L1 Inhibitors Plus Chemotherapy for Endometrial Cancer: A Meta-Analysis of 10 RCTs
by Zhilong Huang·Updated 4d ago
1.3 MB1files
Available on 1 platform
Sign in to view source links and access this dataset
Description
A systematic review and meta-analysis of 10 randomized controlled trials involving 4,052 patients with advanced or metastatic endometrial cancer. The dataset, authored by Zhilong Huang and last updated in June 2026, pools outcomes including progression-free survival, overall survival, and treatment-related adverse events to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors combined with first-line chemotherapy.
Use Cases
Compare overall survival outcomes between combination therapy and chemotherapy alone based on the reported median values.
Analyze the relative risk of different response types (complete, partial, stable, progressive disease) from the pooled meta-analysis results.
Assess the safety profile of the treatment combination based on the reported common adverse events.
Investigate differential treatment benefits between dMMR and pMMR patient subgroups as indicated in the conclusion.
Strengths
Includes data from 10 randomized controlled trials, a standard for high-quality clinical evidence.